In the EMPOWUR trial, patients with OAB wet or dry were randomly assigned 5:5:4 to receive vibegron 75 mg, placebo, or active control (tolterodine 4 mg extended release), respectively, once daily for 12 weeks. In EMPOWUR, OAB wet was defined as an average of ≥8 micturitions and ≥1 UUI episodes per day at baseline, recorded in a 7-day voiding diary; OAB dry was defined as an average of ≥8 micturitions, ≥3 urgency episodes, and <1 UUI episode per day. Patients recorded UUI episodes in a voiding diary for the 7 days leading up to each trial visit. Patients may have had stress or mixed UI episodes, but only average daily UUI (aUUI) episodes were assessed in this analysis. To assess patient-reported QoL, the OAB-q (1-week recall) was completed at baseline and week 12, and PGI items (Severity, Control, Frequency, Leakage, Change) were completed at baseline and weeks 4, 8, and 12. The OAB-q health-related QoL (HRQL) subscale (including coping, concern, sleep, and social interaction domains) and symptom bother subscale are scored 0–100; increases indicate improvement for HRQL scores, whereas decreases indicate improvement for symptom bother score. PGI subscales are scored 1−4 for severity; 1−5 for control, frequency, and leakage; and 1−7 for change, with decreases indicating improvement. This post hoc analysis assessed change from baseline in OAB-q subscale scores and PGI scores among patients who received vibegron and had OAB wet at baseline (ie, full analysis set for incontinence) using descriptive statistics without imputation for missing data. To assess changes in OAB-q and PGI subscale scores, in this post hoc analysis, patients who received vibegron were categorized as aUUI=0 (dry/UUI continent), 0<aUUI<1 (episodic continence), and aUUI ≥1 (incontinent).